Rodman & Renshaw terminated its coverage of China Pharma Holdings CPHI. The rating agency's last rating placed on the company's stock was Market Outperform with a price target of $6. On Monday, CPHI closed the day at $2.14.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst RatingsRodman and Renshaw
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in